<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618640</url>
  </required_header>
  <id_info>
    <org_study_id>BR-DTPP-CT-302</org_study_id>
    <nct_id>NCT04618640</nct_id>
  </id_info>
  <brief_title>To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years</brief_title>
  <acronym>Aladdin</acronym>
  <official_title>A Multicenter, Single-group, Phase III Study to Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years Who Completed the Primary Vaccination Against Diphtheria, Tetanus, Pertussis, and Poliomyelitis by Participating in the Phase III Study, BR-DTPP-CT-301, or by Receiving Routine Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to assess the immunogenicity and safety of DTaP-IPV combination&#xD;
      vaccine administered as a boosting dose to healthy 4 to 6-year-old children who received&#xD;
      three doses of primary immunization against diphtheria, tetanus, pertussis, and polio.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>DTaP-IPV combined vaccine, 0.5mL, imtramuscular</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate after boosting vaccination</measure>
    <time_frame>boosting vaccination after Day 28 [+14 days]</time_frame>
    <description>Antibodies will be measured by enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate for anti-DT, anti-TT, and anti-poliovirus or seropositive (&gt;30 IU/mL) rate for anti-PT and anti-FHA before boosting vaccination</measure>
    <time_frame>Day 1 Pre-vaccination</time_frame>
    <description>Seroprotection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal seroprotection rate for anti-DT and anti-TT (≥ 0.01 IU/mL) before boosting vaccination</measure>
    <time_frame>Day 1 Pre-vaccination</time_frame>
    <description>Seroprotection rate (≥ 0.01 IU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-booster antibody level</measure>
    <time_frame>Day 1 Pre-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-booster antibody level</measure>
    <time_frame>boosting vaccination after Day 28 [+14 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean ratio (GMR) between the pre- and post-booster antibody level</measure>
    <time_frame>Day 1 Pre-vaccination and boosting vaccination after Day 28 [+14 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMR between the pre- and post-booster antibody level in each subgroup depending on the pre-booster antibody level (≥ seroprotective/seropositive level or &lt; seroprotective/seropositive level)</measure>
    <time_frame>Day 1 Pre-vaccination and boosting vaccination after Day 28 [+14 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reverse cumulative distribution curves for pre- and post-booster antibody level</measure>
    <time_frame>Day 1 Pre-vaccination and boosting vaccination after Day 28 [+14 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate for anti-DT, anti-TT, and anti-poliovirus or seropositive (&gt;30 IU/mL) rate for anti-PT and anti-FHA after boosting vaccination</measure>
    <time_frame>boosting vaccination after Day 28 [+14 days]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with post-booster antibody levels for anti-DT and anti-TT ≥1.0 IU/mL</measure>
    <time_frame>boosting vaccination after Day 28 [+14 days]</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">249</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>DTaP-IPV combination vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTaP-IPV 0.5ml IM boosting</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV combination vaccine</intervention_name>
    <description>Dosage and administration: A single intramuscular injection of 0.5 mL will be given to healthy children aged 4 to 6 years</description>
    <arm_group_label>DTaP-IPV combination vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A subject's parent/legal representative provides a written consent after being&#xD;
             informed about the study objective, methods, effect of the study vaccine, and other&#xD;
             relevant information&#xD;
&#xD;
          2. Documented record of the three doses of primary immunization against diphtheria,&#xD;
             tetanus, pertussis, and polio either by participating in the previous study,&#xD;
             BR-DTPP-CT-301 or by following the national immunization schedule under usual clinical&#xD;
             setting (the primary immunization should have been initiated after 6 weeks of age and&#xD;
             at minimal interval of 4 weeks)&#xD;
&#xD;
          3. Receipt of a boosting dose against diphtheria, tetanus, and pertussis until 2 years of&#xD;
             age; therefore, total of four vaccination records against diphtheria, tetanus, and&#xD;
             pertussis and three against polio&#xD;
&#xD;
          4. Healthy male or female children, aged 4 to 6 years on the day of the vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Children aged 7 years or older&#xD;
&#xD;
          2. Previously received DTaP vaccine five times or more, including the doses received in&#xD;
             the BR-DTPP-CT-301 study, either by a combination vaccine or a separate vaccine&#xD;
&#xD;
          3. Previously received IPV vaccine four times or more, including the doses received in&#xD;
             the BR-DTPP-CT-301 study, either by a combination vaccine or a separate vaccine&#xD;
&#xD;
          4. The fourth dose of DTaP vaccine was postponed and administered after 4 years of age&#xD;
&#xD;
          5. Acute febrile illness with fever ≥ 38.0°C (tympanic) on the day of the vaccination&#xD;
&#xD;
          6. Moderate to severe systemic acute illness with or without fever&#xD;
&#xD;
          7. History of diphtheria, tetanus, pertussis, or polio (poliomyelitis)&#xD;
&#xD;
          8. Dysfunctional immune system or congenital or acquired immunodeficiency&#xD;
&#xD;
          9. Had encephalopathy of unknown etiology within 7 days following a previous dose of DTaP&#xD;
             vaccine&#xD;
&#xD;
         10. Received a vaccine other than the protocol-permitted vaccines within 28 days from the&#xD;
             study vaccination day or are planned to receive such a vaccine during the study period&#xD;
&#xD;
         11. Received systemic corticosteroid treatment at immunosuppressive dosage within 28 days&#xD;
             from the study vaccination day or are planned to receive such a treatment during the&#xD;
             study period (exceptionally, administration of prednisolone ≤ 0.5 mg/kg/day for up to&#xD;
             14 continuous days is allowed)&#xD;
&#xD;
         12. Received immunoglobulins or blood products within 90 days before the study vaccination&#xD;
             day or are planned to receive such products during the study period&#xD;
&#xD;
         13. Had severe allergic reaction (e.g. anaphylaxis) to ingredients of the investigational&#xD;
             product or bears such a possibility&#xD;
&#xD;
         14. Currently enrolled in another clinical trial or planned to participate in another&#xD;
             clinical trial&#xD;
&#xD;
         15. Any other reasons that preclude the eligibility of the subject, based on&#xD;
             investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byeonguk Eun</last_name>
    <role>Study Chair</role>
    <affiliation>Eulji University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sunhye IM</last_name>
    <phone>+82-2-780-8454</phone>
    <email>Imsunhye@boryungbio.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seohee Byeon</last_name>
    <phone>+82-2-740-4154</phone>
    <email>seohee@boryungbio.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yun Kyung Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Han Wool Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changwon Fatima Hospital</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang Hyuk Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KeiMyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chun Soo Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seon Hee Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kwang Nam Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Hospital</name>
      <address>
        <city>Iksan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seung Taek Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yong Hoon Jun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ki Hwan Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dae Sun Jo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mediplex Sejong Hospital</name>
      <address>
        <city>Sejong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kyu Yol Rhie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Taek Jin Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin A Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sin Weon Yun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Byeong Uk Eun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Sevrance Christian Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ji Hong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanil General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ji Hye kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dong Ho Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungHee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sung Hoon Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungHee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eun Hye Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yae Jean Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jong Gyun Ahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hyun Joo Jung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jong Hyun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wonju Sevrance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hwang Min Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 1, 2020</last_update_submitted>
  <last_update_submitted_qc>November 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DTaP-IPV</keyword>
  <keyword>Boosting Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

